These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 32847975)

  • 1. The Novel Histone Deacetylase Inhibitor, OBP-801, Induces Apoptosis in Rhabdoid Tumors by Releasing the Silencing of
    Sugimoto Y; Katsumi Y; Iehara T; Kaneda D; Tomoyasu C; Ouchi K; Yoshida H; Miyachi M; Yagyu S; Kikuchi K; Tsuchiya K; Kuwahara Y; Sakai T; Hosoi H
    Mol Cancer Ther; 2020 Oct; 19(10):1992-2000. PubMed ID: 32847975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SNF5 reexpression in malignant rhabdoid tumors regulates transcription of target genes by recruitment of SWI/SNF complexes and RNAPII to the transcription start site of their promoters.
    Kuwahara Y; Wei D; Durand J; Weissman BE
    Mol Cancer Res; 2013 Mar; 11(3):251-60. PubMed ID: 23364536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone deacetylase inhibitor panobinostat induces antitumor activity in epithelioid sarcoma and rhabdoid tumor by growth factor receptor modulation.
    Harttrampf AC; da Costa MEM; Renoult A; Daudigeos-Dubus E; Geoerger B
    BMC Cancer; 2021 Jul; 21(1):833. PubMed ID: 34281526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imprinted CDKN1C is a tumor suppressor in rhabdoid tumor and activated by restoration of SMARCB1 and histone deacetylase inhibitors.
    Algar EM; Muscat A; Dagar V; Rickert C; Chow CW; Biegel JA; Ekert PG; Saffery R; Craig J; Johnstone RW; Ashley DM
    PLoS One; 2009; 4(2):e4482. PubMed ID: 19221586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The histone deacetylase inhibitor OBP-801 has in vitro/in vivo anti-neuroblastoma activity.
    Kaneda D; Iehara T; Kikuchi K; Sugimoto Y; Nakagawa N; Yagyu S; Miyachi M; Konishi E; Sakai T; Hosoi H
    Pediatr Int; 2022 Jan; 64(1):e15159. PubMed ID: 35727889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chidamide, a histone deacetylase inhibitor, functions as a tumor inhibitor by modulating the ratio of Bax/Bcl-2 and P21 in pancreatic cancer.
    Zhao B; He T
    Oncol Rep; 2015 Jan; 33(1):304-10. PubMed ID: 25384499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors.
    Howard TP; Arnoff TE; Song MR; Giacomelli AO; Wang X; Hong AL; Dharia NV; Wang S; Vazquez F; Pham MT; Morgan AM; Wachter F; Bird GH; Kugener G; Oberlick EM; Rees MG; Tiv HL; Hwang JH; Walsh KH; Cook A; Krill-Burger JM; Tsherniak A; Gokhale PC; Park PJ; Stegmaier K; Walensky LD; Hahn WC; Roberts CWM
    Cancer Res; 2019 May; 79(9):2404-2414. PubMed ID: 30755442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells.
    Takai N; Desmond JC; Kumagai T; Gui D; Said JW; Whittaker S; Miyakawa I; Koeffler HP
    Clin Cancer Res; 2004 Feb; 10(3):1141-9. PubMed ID: 14871994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rhabdoid tumor growth is inhibited by flavopiridol.
    Smith ME; Cimica V; Chinni S; Challagulla K; Mani S; Kalpana GV
    Clin Cancer Res; 2008 Jan; 14(2):523-32. PubMed ID: 18223228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-Dose Histone Deacetylase Inhibitor Treatment Leads to Tumor Growth Arrest and Multi-Lineage Differentiation of Malignant Rhabdoid Tumors.
    Muscat A; Popovski D; Jayasekara WS; Rossello FJ; Ferguson M; Marini KD; Alamgeer M; Algar EM; Downie P; Watkins DN; Cain JE; Ashley DM
    Clin Cancer Res; 2016 Jul; 22(14):3560-70. PubMed ID: 26920892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of Histone Deacetylase Inhibitor Sensitivity in Combination with Cyclin-Dependent Kinase Inhibition for the Treatment of Oral Squamous Cell Carcinoma.
    Zhao B; Huang Z; Qin Z; Li Y; Wang T; Wang L; Zhou W; Yu C; Wang X; Yang S; Fan Y; Xiang R
    Cell Physiol Biochem; 2019; 53(1):141-156. PubMed ID: 31237760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A NOXA/MCL-1 Imbalance Underlies Chemoresistance of Malignant Rhabdoid Tumor Cells.
    Ouchi K; Kuwahara Y; Iehara T; Miyachi M; Katsumi Y; Tsuchiya K; Konishi E; Yanagisawa A; Hosoi H
    J Cell Physiol; 2016 Sep; 231(9):1932-40. PubMed ID: 26680268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of a novel HDAC inhibitor OBP-801/YM753 and a PI3K inhibitor LY294002 synergistically induces apoptosis in human endometrial carcinoma cells due to increase of Bim with accumulation of ROS.
    Yoshioka T; Yogosawa S; Yamada T; Kitawaki J; Sakai T
    Gynecol Oncol; 2013 May; 129(2):425-32. PubMed ID: 23403163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
    Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
    Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
    [No Abstract]   [Full Text] [Related]  

  • 15. Inhibition of MYC attenuates tumor cell self-renewal and promotes senescence in SMARCB1-deficient Group 2 atypical teratoid rhabdoid tumors to suppress tumor growth in vivo.
    Alimova I; Pierce A; Danis E; Donson A; Birks DK; Griesinger A; Foreman NK; Santi M; Soucek L; Venkataraman S; Vibhakar R
    Int J Cancer; 2019 Apr; 144(8):1983-1995. PubMed ID: 30230537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aurora A is a repressed effector target of the chromatin remodeling protein INI1/hSNF5 required for rhabdoid tumor cell survival.
    Lee S; Cimica V; Ramachandra N; Zagzag D; Kalpana GV
    Cancer Res; 2011 May; 71(9):3225-35. PubMed ID: 21521802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells.
    Park KC; Heo JH; Jeon JY; Choi HJ; Jo AR; Kim SW; Kwon HJ; Hong SJ; Han KS
    BMC Cancer; 2015 Jan; 15():19. PubMed ID: 25613585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells.
    Kerl K; Ries D; Unland R; Borchert C; Moreno N; Hasselblatt M; Jürgens H; Kool M; Görlich D; Eveslage M; Jung M; Meisterernst M; Frühwald M
    BMC Cancer; 2013 Jun; 13():286. PubMed ID: 23764045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. INI1 induces interferon signaling and spindle checkpoint in rhabdoid tumors.
    Morozov A; Lee SJ; Zhang ZK; Cimica V; Zagzag D; Kalpana GV
    Clin Cancer Res; 2007 Aug; 13(16):4721-30. PubMed ID: 17699849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of apoptosis of lung and esophageal cancer cells treated with the combination of histone deacetylase inhibitor (trichostatin A) and protein kinase C inhibitor (calphostin C).
    Maxhimer JB; Reddy RM; Zuo J; Cole GW; Schrump DS; Nguyen DM
    J Thorac Cardiovasc Surg; 2005 Jan; 129(1):53-63. PubMed ID: 15632825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.